Replies to post #96439 on Biotech Values

[mcbio]

ANDS - downgraded to "hold"

[I can't say I disagree with any of the analysis though it could have been made earlier. The price target might be a bit optimistic as well.]

http://finance.yahoo.com/news/Anadys-shares-fall-after-apf-3359997335.html?x=0&.v=1

Anadys shares fall after downgrade to 'Hold'
Anadys Pharmaceuticals shares fall after Roth Capital downgrades to 'Hold'

NEW YORK (AP) -- Shares of Anadys Pharmaceuticals Inc. fell Wednesday after a Roth Capital Partners analyst issued a downgrade, citing the company's plan for "strategic alternatives" for its key drug candidate.

THE SPARK: Analyst Edward Nash downgraded shares to "Hold" from "Buy" and cut his share price target to $2 from $5.

In May, Anadys retained Lazard Freres & Co. as a strategic adviser to help evaluate options the prospective hepatitis C treatment ANA598. Nash said the company's move leads him to believe that it is no closer to finding a partner for the drug candidate.

THE BIG PICTURE: ANA598 is part of the non-nucleoside class of drugs, which Nash said could be a difficult sell in a competitive market [agreed].

THE ANALYSIS: "We do not dismiss the merits of the drug's potency or the inability to overcome rash issues with additional treatment options, but the concern over the need of a non-nucleoside in the face of such potent other direct acting antivirals is a concern," Nash wrote in a note to clients. "Additionally, unlike HIV, which cannot be cured so other options will most likely be used at some point in treating patients, a higher percentage of patients are clearing virus, from recent studies, that could negate the need for a non-nucleoside regimen.

SHARE ACTION: Anadys stock slipped 10 cents, or 4.7 percent, to $2.01 in afternoon trading. Shares have traded between $1.44 and $3.32 over the last 52 weeks.